Cardiovascular Death Risk in Recovered Mid-Range Ejection Fraction Heart Failure: Insights From Cardiopulmonary Exercise Test.


Journal

Journal of cardiac failure
ISSN: 1532-8414
Titre abrégé: J Card Fail
Pays: United States
ID NLM: 9442138

Informations de publication

Date de publication:
Nov 2020
Historique:
received: 10 01 2020
revised: 13 03 2020
accepted: 17 04 2020
pubmed: 20 5 2020
medline: 19 8 2021
entrez: 20 5 2020
Statut: ppublish

Résumé

Heart failure with midrange ejection fraction (HFmrEF) represents a heterogeneous category where phenotype, as well as prognostic assessment, remains debated. The present study explores a specific HFmrEF subset, namely those who recovered from a reduced EF (rec-HFmrEF) and, particularly, it focuses on the possible additive prognostic role of cardiopulmonary exercise testing. We analyzed data from 4535 patients with HFrEF and 1176 patients with rec-HFmrEF from the Metabolic Exercise combined with Cardiac and Kidney Indexes database. The end point was cardiovascular death at 5 years. The median follow-up was 1343 days (25th-75th range 627-2403 days). Cardiovascular death occurred in 552 HFrEF and 61 rec-HFmrEF patients. The multivariate analysis confirmed an independent role of the MECKI score's variables in HFrEF (C-index = 0.744) whereas, in the rec-HFmrEF group, only age and peak oxygen uptake (pVO Present data support the cardiopulmonary exercise test and, particularly, the peak oxygen uptake, as a useful tool in the rec-HFmrEF prognostic assessment. A peak VO

Sections du résumé

BACKGROUND BACKGROUND
Heart failure with midrange ejection fraction (HFmrEF) represents a heterogeneous category where phenotype, as well as prognostic assessment, remains debated. The present study explores a specific HFmrEF subset, namely those who recovered from a reduced EF (rec-HFmrEF) and, particularly, it focuses on the possible additive prognostic role of cardiopulmonary exercise testing.
METHODS AND RESULTS RESULTS
We analyzed data from 4535 patients with HFrEF and 1176 patients with rec-HFmrEF from the Metabolic Exercise combined with Cardiac and Kidney Indexes database. The end point was cardiovascular death at 5 years. The median follow-up was 1343 days (25th-75th range 627-2403 days). Cardiovascular death occurred in 552 HFrEF and 61 rec-HFmrEF patients. The multivariate analysis confirmed an independent role of the MECKI score's variables in HFrEF (C-index = 0.744) whereas, in the rec-HFmrEF group, only age and peak oxygen uptake (pVO
CONCLUSIONS CONCLUSIONS
Present data support the cardiopulmonary exercise test and, particularly, the peak oxygen uptake, as a useful tool in the rec-HFmrEF prognostic assessment. A peak VO

Identifiants

pubmed: 32428671
pii: S1071-9164(20)30031-2
doi: 10.1016/j.cardfail.2020.04.021
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

932-943

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Damiano MagrÌ (D)

Department of Clinical and Molecular Medicine, Azienda Ospedaliera Sant'Andrea, "Sapienza" Università degli Studi di Roma, Roma, Italy.

Massimo Piepoli (M)

UOC Cardiologia, G da Saliceto Hospital, Piacenza, Italy.

Ugo CorrÀ (U)

Cardiology Department, Istituti Clinici Scientifici Maugeri, IRCCS, Veruno Institute, Veruno, Italy.

Giovanna Gallo (G)

Department of Clinical and Molecular Medicine, Azienda Ospedaliera Sant'Andrea, "Sapienza" Università degli Studi di Roma, Roma, Italy.

Antonello Maruotti (A)

Dipartimento di Giurisprudenza, Economia, Politica e Lingue Moderne - Libera Università Maria Ss Assunta, Roma, Italy; Department of Mathematics, University of Bergen, Bergen, Norway; School of Computing, University of Portsmouth, Portsmouth, UK.

Carlo Vignati (C)

Centro Cardiologico Monzino, IRCCS, Milano, Italy.

Elisabetta Salvioni (E)

Centro Cardiologico Monzino, IRCCS, Milano, Italy.

Massimo Mapelli (M)

Centro Cardiologico Monzino, IRCCS, Milano, Italy.

Stefania Paolillo (S)

Department of Advanced Biomedical Sciences, Federico II University of Naples, Naples, Italy.

Pasquale Perrone Filardi (P)

Department of Advanced Biomedical Sciences, Federico II University of Naples, Naples, Italy.

Davide Girola (D)

Clinica Hildebrand Centro di riabilitazione Brissago, Brissago, Switzerland.

Marco Metra (M)

Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy.

Angela B Scardovi (AB)

Cardiology Division, Santo Spirito Hospital, Roma, Italy.

Rocco Lagioia (R)

Division of Cardiology, "S. Maugeri" Foundation, IRCCS, Institute of Cassano Murge, Bari, Italy.

Giuseppe Limongelli (G)

Cardiologia SUN, Ospedale Monaldi (Azienda dei Colli), Seconda Università di Napoli, Napoli, Italy.

Michele Senni (M)

Department of Cardiology, Heart Failure and Heart Transplant Unit, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy.

Domenico Scrutinio (D)

Division of Cardiology, "S. Maugeri" Foundation, IRCCS, Institute of Cassano Murge, Bari, Italy.

Michele Emdin (M)

Fondazione Gabriele Monasterio, CNR-Regione Toscana, Pisa, Italy; Life Science Institute, Scuola Superiore Sant'Anna, Pisa, Italy.

Claudio Passino (C)

Fondazione Gabriele Monasterio, CNR-Regione Toscana, Pisa, Italy; Life Science Institute, Scuola Superiore Sant'Anna, Pisa, Italy.

Carlo Lombardi (C)

Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy.

Gaia Cattadori (G)

Unità Operativa Cardiologia Riabilitativa, Multimedica IRCCS, Milano, Italy.

Gianfranco Parati (G)

Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy; Department of Cardiovascular, Neural and Metabolic Sciences, San Luca Hospital, Istituto Auxologico Italiano, Milan, Italy.

Mariantonietta Cicoira (M)

Section of Cardiology, Department of Medicine, University of Verona, Verona, Italy.

Michele Correale (M)

Department of Cardiology, University of Foggia, Foggia, Italy.

Maria Frigerio (M)

Dipartimento Cardiologico "A. De Gasperis", Ospedale Cà Granda- A.O. Niguarda, Milano, Italy.

Francesco Clemenza (F)

Department for the Treatment and Study of Cardiothoracic Diseases and Cardiothoracic Transplantation IRCCS - ISMETT, Palermo, Italy.

Maurizio Bussotti (M)

Cardiac Rehabilitation Unit, Fondazione Salvatore Maugeri, IRCCS, Scientific Institute of Milan, Milan, Italy.

Marco Guazzi (M)

Cardiology University Department, Heart Failure Unit and Cardiopulmonary Laboratory, IRCCS Policlinico San Donato, San Donato Milano, Italy.

Roberto Badagliacca (R)

Dipartimento di Scienze Cardiovascolari, Respiratorie, Nefrologiche, Anestesiologiche e Geriatriche, "Sapienza", Rome University, Rome, Italy.

Susanna Sciomer (S)

Dipartimento di Scienze Cardiovascolari, Respiratorie, Nefrologiche, Anestesiologiche e Geriatriche, "Sapienza", Rome University, Rome, Italy.

Andrea DI Lenarda (A)

Cardiovascular Center, Health Authority n°1 and University of, Trieste, Trieste, Italy.

Aldo Maggioni (A)

ANMCO Research Center, Firenze, Italy.

Gianfranco Sinagra (G)

Cardiovascular Department, Ospedali Riuniti and University of Trieste, Trieste, Italy.

Massimo Volpe (M)

Department of Clinical and Molecular Medicine, Azienda Ospedaliera Sant'Andrea, "Sapienza" Università degli Studi di Roma, Roma, Italy; IRCCS Neuromed, Pozzilli (Isernia), Italy.

Piergiuseppe Agostoni (P)

Centro Cardiologico Monzino, IRCCS, Milano, Italy; Department of Clinical sciences and Community Health, Cardiovascular Section, University of Milano, Milano, Italy. Electronic address: piergiuseppe.agostoni@unimi.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH